- Home
- PLSE vs ATAI Comparison
PLSE vs ATAI Comparison
Compare PLSE & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLSE | ATAI |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2015 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PLSE | ATAI |
|---|---|---|
| Price | $25.34 | $4.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $22.00 | $15.88 |
| AVG Volume (30 Days) | 351.3K | ★ 4.1M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,089,000.00 |
| Revenue This Year | $840.00 | N/A |
| Revenue Next Year | $287.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $12.56 | $2.00 |
| 52 Week High | $27.98 | $6.73 |
Technical Indicators
Market Signals| Indicator | PLSE | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 56.83 | 61.78 |
| Support Level | $17.58 | $3.46 |
| Resistance Level | $27.14 | $4.68 |
| Average True Range (ATR) | 1.88 | 0.22 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 67.93 | 93.94 |
Price Performance
Historical ComparisonAbout PLSE Pulse Biosciences Inc (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.